Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans may guide treatment of hidden fungal infection in cancer patients

NCT ID NCT01916057

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether a special type of PET scan can help doctors diagnose and treat a rare fungal infection of the liver and spleen in people with blood cancer or those who had a stem cell transplant. The infection often appears after severe neutropenia (low white blood cells). The study enrolled 100 adults and compared PET scan results with other tests over time. The goal was to see if the scan could guide treatment decisions, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG PET scan
What this could lead to
If successful, this could show that PET scans are a useful tool for managing treatment of hepatosplenic candidiasis in vulnerable patients.
What could go wrong
This is a small pilot study, not a large trial. It is designed to gather information, not to prove a new treatment works. The results may not change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Nov 2013

Finished

Feb 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients' inclusion criteria: * Adults aged ≥18 years-old * Hospitalized for hematological malignancy or hematopoietic stem cell transplantation * Recent (\>2months), prolonged (\>10 days), profound (\>100 PMN/mm3), feverish neutropenia * Suspected hepatosplenic candidiasis (typical small nodular lesions on abdominal RMI or CT) Patients' exclusion criteria: \- hepatosplenic lesions of other proven origin Patients' non-inclusion criteria: * Life expectancy \>3 months * Pregnancy * HIV infection * Hepatic biopsy within 3 weeks before 18F-FDG PET scan

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic disseminated candidiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disseminated candidiasis hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm immune reconstitution inflammatory syndrome inherited disease susceptibility Invasive Fungal Infections neutropenia systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic disseminated candidiasis Hematological malignancies Hematopoietic stem cell transplantation Invasive fungal disease Neutropenia

Contacts and locations

Locations

  • Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.